Several potential risk factors for PT after HSCT have been suggested, including graft-versus-host disease (GVHD), doses of infused CD34+ cells, disease status, cytomegalovirus (CMV) infection, and donor-specific antibodies (6, 8–11). This evidence concerns the gene CD34 and graft versus host disease.